Altimmune (ALT) had its "sell (d-)" rating reaffirmed by
Weiss Ratings.
Anti-Aging Protein Research Takes a Step Forward with Cell Cloning
Altimmune (ALT) is now covered by Truist Financial Corporation. They set a "buy" rating and a $12.00 price target on the stock.
Altimmune (ALT) had its price target raised by HC Wainwright from $12.00 to $25.00. They now have a "buy" rating on the stock.
Altimmune Touts Pemvidutide Progress, Targets MASH Phase 3 Start and Q3 AUD Readout at Barclays Chat [Yahoo! Finance]